Over The Counter (OTC)

GSK's Flonase tops allergy category

The new OTC medication almost hit $100 million in sales in its first 16 weeks on the market.

Poll: Patients rely on others to help with OTC choices

Poll: Patients rely on others to help with OTC choices

By

A Pfizer poll shows patients rely on over-the-counter medications but need help finding the right treatment.

Johnson & Johnson, GSK settle dispute over OTC advertising claims

Johnson & Johnson, GSK settle dispute over OTC advertising claims

By

Johnson & Johnson alleged that misleading advertising threatened the $13.2 million in average weekly sales it makes during prime allergy sales season.

Japan seeks more OTC medications

The government is asking consumers which ones they prefer.

Pfizer takes issue with Little Remedies

The drugmaker, which markets the Dimetapp cough and cold line, sent a complaint to the Better Business Bureaus.

GSK re-launches OTC diet pill

The over-the-counter weight-loss drug Alli saw a return to drugstores this week after a year hiatus.

GSK launches Flonase OTC

GSK launches Flonase OTC

By

The initial push includes a behind-the-scenes Tumblr and broadcast plans are being finalized.

Pfizer challenges Novartis OTC ad claims

Pfizer challenges Novartis OTC ad claims

By

Pfizer, through the Better Business Bureau's National Advertising Division, disputes that Novartis's Theraflu 'starts to work in the body in 5 minutes.'

New OTC Nexium approved

The FDA has approved a 24-hour version of Pfizer's heartburn medication.

FDA seeks flexible OTC review process

The agency says is it time to update the onerous decades-old review process.

FDA panel to review NSAIDs this month

A panel is meeting February 10 to discuss revoking the OTC status of some medications.

Discontinued OTC asthma med may make comeback

An FDA committee is poised to review a new Primatene Mist in February.

J&J posts third-quarter progress

J&J posts third-quarter progress

By

The company beat consensus estimates, with particular sales strengths from its pharmaceuticals division.

Business briefs: Sanofi, Gilead, Eli Lilly, Boehringer, Girl Scouts

Sanofi pulls GLP-1 diabetes med from FDA review; Gilead files oncology drug; BI/Lilly reveals results of head-to-head trial of its SGLT2 inhibitor vs. Januvia; BI campaign animates heartburn market; Girl Scouts take on mental health

Valeant leverages Rx sales force, YouTube for OTC brand

Valeant leverages Rx sales force, YouTube for OTC brand

By

The company is supporting its professional pitch for the acne drug with a micro-targeted marketing strategy.

Business briefs: Sanofi, Celgene, plus changing cancer definitions

Sanofi may make OTC history; Celgene joins a new collaboration; and the US Task Force of Preventative Medicine wants to make lung cancer screening the norm

Business briefs: Teva, AbbVie, Novartis, Wockhardt

FDA grants Teva three years exclusivity to sell Plan B OTC for all ages; FDA gives Humira a thumbs-down for spondyloarthritis; a UK vaccine committee rejects Novartis' meningitis B shot; and Wockhardt gets a warning letter from FDA for its manufacturing practices at an Indian plant.

Not buying it: Medical professionals go generic, study shows

By

Researchers quantify the rate at which doctors, nurses and pharmacists buy off-label OTC drugs.

Merck's Heller on how to get more women into the C-suite

Merck's Heller on how to get more women into the C-suite

By

Bridgette Heller, Merck EVP and president of its consumer care division, adjured life-sci managers to enable women to unleash the full power of their knowledge and ideas to drive growth in the business.

For consumers, price isn't just a financial factor

By

A pair of studies suggests that consumers are hungry for information, and that price determines how patients perceive their risk for life-threatening conditions.

J&J OTC sales slipped 3% in 2012 worldwide

By

CEO Alex Gorsky said OTC brands are coming back. Meanwhile, pharmaceutical sales provided ballast to the year's numbers.

Company news: Sanofi, Elsevier

Rolaids gets a French twist, and Elsevier packs the second week of the year with two news items.

Company news: Novo Nordisk

Novo Nordisk has launched a hemophilia app; and a report says the Chinese OTC market is going gangbusters

Excedrin relaunch features Sparks, "Thank yous" from migraine sufferers

Excedrin relaunch features Sparks, "Thank yous" from migraine sufferers

By

Novartis is hyping its relaunch of Excedrin with a celebrity spokesperson, a migraine app and a survey of women migraine sufferers - along with print and out-of-home ads, radio promotions, direct mail and social media.

Study: OTC ads are so over risk info

Study: OTC ads are so over risk info

By

A study of advertising for OTC switches found that presentation of risk information plummeted once the products advertised escaped the purview of the FDA.

Company news: GSK, Novartis and Boehringer Ingelheim

GlaxoSmithKline continues to shed businesses, but can't shake its weight-loss drug Alli (orlistat).

People news: Novartis, Qforma and Precision Health Media

Novartis named Brian McNamara as division head of OTC, replacing J&J veteran Naomi Kelman, who spent a year in the role.

As GSK jettisons consumer brands, smaller marketer sees boon

As GSK jettisons consumer brands, smaller marketer sees boon

By

GlaxoSmithKline divested North American OTC drugs worth about $200 million in sales, a portfolio that seemed like a good strategic fit for buyer Prestige Brands Holdings.

Bon Jovi enlists in Advil's battle with Tylenol

Bon Jovi enlists in Advil's battle with Tylenol

By

Jon Bon Jovi is the latest celebrity pitchman for Pfizer Consumer Healthcare's Advil.

Advil Congestion effort ties traffic gridlock to cold and flu misery

Advil Congestion effort ties traffic gridlock to cold and flu misery

By

Don't tell the New York Post, but Pfizer is boosting bike lanes as part of an Advil promotion.

Email Newsletters


Investment in healthcare IT stands at an all-time high. The government has spent billions to promote EHR adoption. Yet the physician wish list is a mile long, while hospitals and patients are not where they need to be. To peel back the layers of what we've all been waiting for in the Great Data Capture of the 21st Century, and to review the changes enabling the healthcare data ecosystem to coexist, MM&M presents this e-Book. Click here.


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.